Approaches for relapsed CLL after chemotherapy-free frontline regimens

Novel agents, including Bruton’s tyrosine kinase inhibitors (BTKi; ibrutinib, acalabrutinib), venetoclax, and phosphatidylinositol 3-kinase inhibitors (PI3Ki; idelalisib, duvelisib), have fundamentally changed the chronic lymphocytic leukemia (CLL) treatment landscape, allowing for a chemotherapy-fr...

Full description

Saved in:
Bibliographic Details
Published in:Hematology Am Soc Hematol Educ Program
Main Authors: Roeker, Lindsey E., Mato, Anthony R.
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2020
Subjects:
A Map for the Changing Landscape of CLL
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7727527/
https://ncbi.nlm.nih.gov/pubmed/33275712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2020000168
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items